Skip to main content

Table 1 Baseline characteristics of study subjects

From: Effects of pitavastatin versus atorvastatin on the peripheral endothelial progenitor cells and vascular endothelial growth factor in high-risk patients: a pilot prospective, double-blind, randomized study

  Pitavastatin Atorvastatin P value
(n = 13) (n = 13)
Age (years) 60.1 ± 7.3 60.5 ± 10.3 0.90
Male, n (%) 6 (46.2%) 5 (38.5%) 0.69
Type 2 Diabetes Mellitus, n (%) 8 (61.5%) 11 (84.6%) 0.38
Hypertension, n (%) 10 (70.7%) 7 (53.8%) 0.67
Coronary artery disease, n (%) 2 (15.4%) 0 (0.0%) 0.14
Current smoker, n (%) 2 (15.4%) 1 (7.7%) 0.54
Waist Circumference (cm) 87.7 ± 6.3 91.7 ± 13.1 0.33
BMI (kg/m2) 25.2 ± 3.9 27.1 ± 3.8 0.22
SBP (mmHg) 118.2 ± 12.6 127.5 ± 19.6 0.17
DBP (mmHg) 76.2 ± 8.9 80.8 ± 11.1 0.26
HR (/min) 73.5 ± 11.7 75.7 ± 10.9 0.63
Creatinine (μmol/L) 76.9 ± 19.4 70.7 ± 17.7 0.25
ALT (U/L) 21.7 ± 13.5 33.6 ± 21.1 0.10
Glucose (mmo/L) 6.98 ± 1.39 6.28 ± 1.04 0.16
A1c (%) 6.8 ± 1.1 6.3 ± 0.5 0.18
Medication    
Metformin, n (%) 8 (61.5%) 11 (84.6%) 0.14
DPP-4 inhibitors, n (%) 2 (15.4%) 1 (7.7%) 0.54
PPAR-γ agonists, n (%) 0 (0%) 1 (7.7%) 0.31
ARB, n (%) 3 (23.1%) 4 (30.8%) 0.66
ACEI, n (%) 3 (23.1%) 2 (15.4%) 0.62
CCB, n (%) 5 (38.5%) 3 (23.1%) 0.40
Beta-blockers, n (%) 2 (15.4%) 2 (15.4%) 1.00
Diuretics, n (%) 1 (7.7%) 4 (30.8%) 0.14
Aspirin, n (%) 3 (23.1%) 1 (7.7%) 0.28
  1. Values are mean ± standard deviation (SD) or number (%). ARB: angiotensin II receptor blockers; ACEI: angiotensin converting enzyme inhibitors; BMI: body mass index; CCB: calcium channel blockers; DBP: diastolic blood pressure; HR: heart beats ALT: analine amiontransferase; DPP-4 inhibitors: dipeptidyl peptidase-4 inhibitors; PPAR-γ agonists: peroxisome proliferator activator receptor-gamma agonists, SBP: systolic blood pressure.